Business
Dyadic Reports 2024 Year-End Financial Results and Business Updates
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products
About this update from Dyadic International, Inc.
[{"type":"image","alt":"Dyadic International, Inc.","displaySize":"","headline":null,"caption":"Dyadic International, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":295,"height":229,"url":"https://media.zenfs.com/en/globenewswire.com/346a61dbf291488ea30b6fd65e81e681"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gy0FmjKeMiJzIWa7r133nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/346a61dbf291488ea30b6fd65e81e681","width":295,"height":229}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower cost","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Growth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applications","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued advancements in animal and human health","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and investment-grade securities of $9.3 million as of December 31, 2024","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Financial results and business update conference call scheduled for 5:00 pm ET today","length":84,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":786,"olType":false},{"type":"text","content":"JUPITER, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non- pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the full year 2024, highlighting significant progress in commercializing its prop...